File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospects

TitleTreatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospects
Authors
KeywordsDrug Resistant
Fluoroquinolone
New Drugs
Treatment
Tuberculosis
Issue Date2009
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecp
Citation
Expert Review Of Clinical Pharmacology, 2009, v. 2 n. 4, p. 405-421 How to Cite?
AbstractDrug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR)-TB requires alternative specific chemotherapy, comprising drugs with higher cost and greater toxicity delivered on a programmatic basis. The development of new anti-TB drugs would help to prevent and treat MDR-TB. Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both drug-susceptible and drug-resistant disease. The roles of surgery and immunotherapy in the management of MDR-TB require further evaluation. The recent emergence of extensively drug-resistant TB poses a serious challenge to the global control of TB. In order to combat extensively drug-resistant TB, strengthening of directly observed treatment, short-course and drug-resistance programs, alongside other strategies, including the development of newer diagnostics and drugs, is mandatory. © 2009 Expert Reviews Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/157557
ISSN
2015 Impact Factor: 2.488
2015 SCImago Journal Rankings: 0.794
References

 

DC FieldValueLanguage
dc.contributor.authorTam, CMen_US
dc.contributor.authorYew, WWen_US
dc.contributor.authorYuen, KYen_US
dc.date.accessioned2012-08-08T08:51:14Z-
dc.date.available2012-08-08T08:51:14Z-
dc.date.issued2009en_US
dc.identifier.citationExpert Review Of Clinical Pharmacology, 2009, v. 2 n. 4, p. 405-421en_US
dc.identifier.issn1751-2433en_US
dc.identifier.urihttp://hdl.handle.net/10722/157557-
dc.description.abstractDrug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR)-TB requires alternative specific chemotherapy, comprising drugs with higher cost and greater toxicity delivered on a programmatic basis. The development of new anti-TB drugs would help to prevent and treat MDR-TB. Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both drug-susceptible and drug-resistant disease. The roles of surgery and immunotherapy in the management of MDR-TB require further evaluation. The recent emergence of extensively drug-resistant TB poses a serious challenge to the global control of TB. In order to combat extensively drug-resistant TB, strengthening of directly observed treatment, short-course and drug-resistance programs, alongside other strategies, including the development of newer diagnostics and drugs, is mandatory. © 2009 Expert Reviews Ltd.en_US
dc.languageengen_US
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/loi/ecpen_US
dc.relation.ispartofExpert Review of Clinical Pharmacologyen_US
dc.subjectDrug Resistanten_US
dc.subjectFluoroquinoloneen_US
dc.subjectNew Drugsen_US
dc.subjectTreatmenten_US
dc.subjectTuberculosisen_US
dc.titleTreatment of multidrug-resistant and extensively drug-resistant tuberculosis: Current status and future prospectsen_US
dc.typeArticleen_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1586/ecp.09.19en_US
dc.identifier.scopuseid_2-s2.0-70249140575en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70249140575&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume2en_US
dc.identifier.issue4en_US
dc.identifier.spage405en_US
dc.identifier.epage421en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTam, CM=7201442997en_US
dc.identifier.scopusauthoridYew, WW=7005934631en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats